Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Xvivo Perfusion Approved to Launch Lung Transplant Product in China

publication date: Feb 4, 2022

Sweden's Xvivo Perfusion AB announced its ready-to-use lung perfusion product, Perfadex Plus, was approved for China use with lung transplants. Perfadex Plus facilitates flushing, cold static storage and transportation of donated lungs. Xvivo says Perfadex Plus, and the original product, Perfadex, are used by more than 90% of all lung transplant clinics in the world. A lung transplant is the last resort for patients with end-stage lung disease. China is now the second largest transplant market in the world. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital